← Back to Patent Explorer
US4518598A Expired / Lapsed US ⏱️ 0.0 years remaining

1,2,4-Triazole-3-amines, their pharmaceutical compositions and method of use

Assignee: Glaxo Group Ltd
•
Filing: 1984-01-09
•
Granted: 1985-05-21
•
Expires: 2004-01-09
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts, and hydrates thereof. The substituents are defined in the specification. The compounds show pharmacological activity as selective histamine H 2 -antagonists.

Inventors

  • 👤 Roger Hayes
  • 👤 David E. Bays
  • 👤 John W. M. Mackinnon
  • 👤 Linda Carey
  • 👤 Philip Blatcher

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-29 04:08
CPC Classifications
C; C07; C07D; C07D239/00; C07D239/02; C07D239/24; C07D239/28; C07D239/46; C07D239/47; C07C; C07C279/00; C07C279/28; C07D249/00; C07D249/02; C07D249/08; C07D249/10; C07D249/14; C07D257/00; C07D257/02; C07D257/04; C07D257/06; C07D295/00; C07D295/04; C07D295/08; C07D295/096; C07D471/00; C07D471/02; C07D471/04

Claims Analysis

Total Claims: 7
Claim 1
Independent Claim 849 words
A compound of formula (I) ##STR22## or a physiologically acceptable salt or hydrate thereof, in which R 1 represents hydrogen, C 1-14 alkyl, C 3-8 cycloalkyl, C 3-6 alkenyl, C 3-6 alkynyl, ar C 1-6 alkyl, trifluoro C 1-6 alkyl, heteroaralkyl, or C 1-6 alkyl substituted by C 3-8 cycloalkyl, hydroxy, C 1-6 alkoxy, amino, C 1-6 alkylamino or di C 1-6 alkylamino; and R 2 represents hydrogen or a C 1-4 alkyl group; or R 1 and R 2 together with the nitrogen atom to which they are attached form piperidino, morpholino, 4-methyl piperidino, pyrrolidino, hexamethyleneimino or tetrahydropyridino; Alk represents a straight or branched alkylene chain of 1 to 3 carbon atoms; Q represents a benzene ring in which incorporation into the rest of the molecule is through bonds at the 1- and 3- or 1- and 4-positions; R 5 represents hydrogen or acyl; n and m, which may be the same or different, are each 1 or 2; and R 3 represents hydrogen, C 1-6 alkyl, C 3-6 alkenyl, ar C 1-6 alkyl, hydroxy C 2-6 alkyl, C 1-6 alkoxy C 2-6 alkyl or C 1-4 alkanoyloxy C 2-6 alkyl; R 7 represents hydrogen, C 1-6 alkyl, C 3-6 alkenyl, ar C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkyl, acyloxy C 1-6 alkyl, C 1-6 alkylthio C 1-6 alkyl, arylthio C 1-6 alkyl, aryloxy C 1-6 alkyl, ar C 1-6 alkyloxy C 1-6 alkyl, or the group (CH 2 ) q R 6 where q is zero, 1, 2, 3, 4, 5, or 6 and the alkylene chain (CH 2 ) q may be straight or branched; and R 6 is hydroxy, C 1-6 alkoxy, nitro, heteroaryl, tetrahydropyranyloxy, or CH 2 NHC(═X)NHR 9 where X represents NCN, NSO 2 Methyl, NSO 2 Phenyl or CHNO 2 and R 9 is C 1-6 alkyl; or R 6 is the group NR 10 R 11 , where R 10 is hydrogen or C 1-6 alkyl; and R 11 is hydrogen, C 1-6 alkyl, C 3-6 alkenyl, aryl, ar C 1-6 alkyl, or heteroaralkyl, or R 11 is the group SO 2 R 12 where R 12 is C 1-6 alkyl or aryl; or R 11 is the group COR 13 where R 13 is hydrogen, C 1-6 alkyl, aryl, ar C 1-6 alkyl, C 1-6 alkoxy, halomethyl, heteroaryl, heteroaralkyl or the group NHR 14 where R 14 is hydrogen, C 1-6 alkyl, C 3-8 cycloalkyl, aryl or ar C 1-6 alkyl; or R 10 and R 11 together represent the group ═CR 15 R 16 where R 15 represents aryl or heteroaryl and R 16 represents hydrogen or C 1-6 alkyl; or R 6 is the group SO 2 R 17 in which R 17 is hydroxy, C 1-6 alkyl, aryl or the group NR 18 R 19 where R 18 and R 19 , which may be the same or different, each represents hydrogen or C 1-6 alkyl; or R 6 is the group COR 20 where R 20 is hydrogen, hydroxy, C 1-6 alkoxy, aryloxy, ar C 1-6 alkyloxy, C 1-6 alkyl, aryl, ar C 1-6 alkyl, or the group NR 21 R 22 where R 21 is hydrogen or C 1-6 alkyl optionally substituted by a hydroxy or C 1-6 alkoxy group; and R 22 is hydrogen, C 1-6 alkyl (optionally substituted by a hydroxy or C 1-6 alkoxy group), C 3-6 alkenyl, aryl, ar C 1-6 alkyl or C 3-8 cycloalkyl, or NR 21 R 22 forms a pyrrolidino ring which may be optionally substituted by hydroxy or one or two C 1-3 alkyl groups; or R 6 is the group CR 23 ═NR 24 where R 23 is hydrogen, C 1-6 alkyl, aryl or ar C 1-6 alkyl and R 24 is hydroxy, C 1-6 alkoxy, ar C 1-6 alkyloxy or --NHC(═Y)NH 2 where Y is oxygen or sulphur; or R 3 and R 7 taken together represent --CH═CH-- 2 or --(CH 2 ) 4 --; with the proviso that when the group R 6 contains a carbon atom through which it is linked to the alkylene group (CH 2 ) q then the total number of carbon atoms in the resulting chain is not greater than 6, that is, q is not greater than 5; and wherein the term aryl as a group or part of a group means phenyl or phenyl substituted with one or more C 1-3 alkyl or alkoxy groups or halogen atoms; the term acyl or the acyl portion of an acyloxyalkyl group means an aroyl, aralkanoyl or C 1-6 alkanoyl group; the term heteroaryl as a group or part of a group means thienyl, pyrrolyl, pyridyl, furyl or thiazolyl, the heteroaryl ring may be unsubstituted or substituted by C 1-3 alkyl, C 1-3 alkoxy, hydroxy C 1-6 alkyl, amino C 1-6 alkyl, C 1-6 alkylamino C 1-6 alkyl, di C 1-6 alkylamino C 1-6 alkyl or halogen, the alkyl portion of a heteroaralkyl group is a straight or barnched C 1-4 alkyl chain, and the heteroaryl ring is linked to the alkyl portion through a carbon atom.
Claim 2
Dependent Claim 849 words
A compound of formula (I) ##STR22## or a physiologically acceptable salt or hydrate thereof, in which R 1 represents hydrogen, C 1-14 alkyl, C 3-8 cycloalkyl, C 3-6 alkenyl, C 3-6 alkynyl, ar C 1-6 alkyl, trifluoro C 1-6 alkyl, heteroaralkyl, or C 1-6 alkyl substituted by C 3-8 cycloalkyl, hydroxy, C 1-6 alkoxy, amino, C 1-6 alkylamino or di C 1-6 alkylamino; and R 2 represents hydrogen or a C 1-4 alkyl group; or R 1 and R 2 together with the nitrogen atom to which they are attached form piperidino, morpholino, 4-methyl piperidino, pyrrolidino, hexamethyleneimino or tetrahydropyridino; Alk represents a straight or branched alkylene chain of 1 to 3 carbon atoms; Q represents a benzene ring in which incorporation into the rest of the molecule is through bonds at the 1- and 3- or 1- and 4-positions; R 5 represents hydrogen or acyl; n and m, which may be the same or different, are each 1 or 2; and R 3 represents hydrogen, C 1-6 alkyl, C 3-6 alkenyl, ar C 1-6 alkyl, hydroxy C 2-6 alkyl, C 1-6 alkoxy C 2-6 alkyl or C 1-4 alkanoyloxy C 2-6 alkyl; R 7 represents hydrogen, C 1-6 alkyl, C 3-6 alkenyl, ar C 1-6 alkyl, C 1-6 alkoxy C 1-6 alkyl, acyloxy C 1-6 alkyl, C 1-6 alkylthio C 1-6 alkyl, arylthio C 1-6 alkyl, aryloxy C 1-6 alkyl, ar C 1-6 alkyloxy C 1-6 alkyl, or the group (CH 2 ) q R 6 where q is zero, 1, 2, 3, 4, 5, or 6 and the alkylene chain (CH 2 ) q may be straight or branched; and R 6 is hydroxy, C 1-6 alkoxy, nitro, heteroaryl, tetrahydropyranyloxy, or CH 2 NHC(═X)NHR 9 where X represents NCN, NSO 2 Methyl, NSO 2 Phenyl or CHNO 2 and R 9 is C 1-6 alkyl; or R 6 is the group NR 10 R 11 , where R 10 is hydrogen or C 1-6 alkyl; and R 11 is hydrogen, C 1-6 alkyl, C 3-6 alkenyl, aryl, ar C 1-6 alkyl, or heteroaralkyl, or R 11 is the group SO 2 R 12 where R 12 is C 1-6 alkyl or aryl; or R 11 is the group COR 13 where R 13 is hydrogen, C 1-6 alkyl, aryl, ar C 1-6 alkyl, C 1-6 alkoxy, halomethyl, heteroaryl, heteroaralkyl or the group NHR 14 where R 14 is hydrogen, C 1-6 alkyl, C 3-8 cycloalkyl, aryl or ar C 1-6 alkyl; or R 10 and R 11 together represent the group ═CR 15 R 16 where R 15 represents aryl or heteroaryl and R 16 represents hydrogen or C 1-6 alkyl; or R 6 is the group SO 2 R 17 in which R 17 is hydroxy, C 1-6 alkyl, aryl or the group NR 18 R 19 where R 18 and R 19 , which may be the same or different, each represents hydrogen or C 1-6 alkyl; or R 6 is the group COR 20 where R 20 is hydrogen, hydroxy, C 1-6 alkoxy, aryloxy, ar C 1-6 alkyloxy, C 1-6 alkyl, aryl, ar C 1-6 alkyl, or the group NR 21 R 22 where R 21 is hydrogen or C 1-6 alkyl optionally substituted by a hydroxy or C 1-6 alkoxy group; and R 22 is hydrogen, C 1-6 alkyl (optionally substituted by a hydroxy or C 1-6 alkoxy group), C 3-6 alkenyl, aryl, ar C 1-6 alkyl or C 3-8 cycloalkyl, or NR 21 R 22 forms a pyrrolidino ring which may be optionally substituted by hydroxy or one or two C 1-3 alkyl groups; or R 6 is the group CR 23 ═NR 24 where R 23 is hydrogen, C 1-6 alkyl, aryl or ar C 1-6 alkyl and R 24 is hydroxy, C 1-6 alkoxy, ar C 1-6 alkyloxy or --NHC(═Y)NH 2 where Y is oxygen or sulphur; or R 3 and R 7 taken together represent --CH═CH-- 2 or --(CH 2 ) 4 --; with the proviso that when the group R 6 contains a carbon atom through which it is linked to the alkylene group (CH 2 ) q then the total number of carbon atoms in the resulting chain is not greater than 6, that is, q is not greater than 5; and wherein the term aryl as a group or part of a group means phenyl or phenyl substituted with one or more C 1-3 alkyl or alkoxy groups or halogen atoms; the term acyl or the acyl portion of an acyloxyalkyl group means an aroyl, aralkanoyl or C 1-6 alkanoyl group; the term heteroaryl as a group or part of a group means thienyl, pyrrolyl, pyridyl, furyl or thiazolyl, the heteroaryl ring may be unsubstituted or substituted by C 1-3 alkyl, C 1-3 alkoxy, hydroxy C 1-6 alkyl, amino C 1-6 alkyl, C 1-6 alkylamino C 1-6 alkyl, di C 1-6 alkylamino C 1-6 alkyl or halogen, the alkyl portion of a heteroaralkyl group is a straight or barnched C 1-4 alkyl chain, and the heteroaryl ring is linked to the alkyl portion through a carbon atom.
Claim 3
Dependent Claim 342 words
A compound as claimed in claim 1 in which R 1 represents C 1-8 alkyl, C 1-4 alkyl substituted by a trifluoromethyl group, C 2-4 alkyl substituted by hydroxy or a di C 1-3 alkyl amino group, C 5-7 cycloalkyl, C 3-5 alkenyl, phenyl C 1-3 alkyl, or a heteroaryl C 1-3 alkyl group where the heteroaryl ring contains one heteroatom; R 2 represents hydrogen or methyl; or R 1 R 2 N as defined in claim 1; Alk represents methylene; R 3 represents hydrogen, C 1-6 alkyl, or hydroxy C 2-4 alkyl or R 3 and R 7 , taken together, represent --CH═CH-- 2 or --(CH 2 ) 4 --; Q represents a benzene ring incorporated into the rest of the molecule through bonds at the 1- and 3-positions; R 5 represents hydrogen or C 1-6 alkanoyl; n and m both represent 1, or one of n and m represents 2; R 7 represents C 1-6 alkoxy C 1-6 alkyl, C 1-6 alkylthio C 1-6 alkyl, C 1-6 alkanoyloxy C 1-6 alkyl, benzyl, or --CH═NOH; or R 7 represents the group (CH 2 ) q R 6 where q is zero, 1, 2, or 3, and R 6 represents hydroxyl, CH 2 NHSO 2 R 12 (where R 12 is C 1-6 alkyl), CH 2 NHC(═X)NHCH 3 (where X═NCN or CHNO 2 ), SO 2 R 17 (where R 17 is C 1-6 alkyl), or R 6 represents COR 20 where R 20 is hydroxyl or NR 21 R 22 and R 21 and R 22 independently represent hydrogen or C 1-3 alkyl or R 21 and R 22 together with the nitrogen atom to which they are attached represent a pyrrolidino ring; or R 6 represents the group NR 10 R 11 where R 10 represents hydrogen and R 11 is hydrogen or COR 13 , where R 13 represents hydrogen, C 1-6 alkyl, phenyl, benzyl, C 1-6 alkoxy, NH phenyl, or R 10 and R 11 together represent the group ═CH 15 where R 15 is phenyl or pyridyl.
Claim 4
Dependent Claim 86 words
A compound as claimed in claim 1 in which R 5 represents hydrogen or a C 1-4 alkanoyl group; R 3 represents hydrogen, C 1-6 alkyl, C 3-6 alkenyl, ar C 1-6 alkyl, where aryl is as defined in claim 6, hydroxy C 2-6 alkyl or C 1-6 alkoxy C 2-6 alkyl; R 7 is as defined in claim 1, except that R 6 does not represent tetrahydropyrangloxy; and R 1 , R 2 , Alk, Q, n and m are as defined in claim 1.
Claim 5
Dependent Claim 51 words
A compound as claimed in claim 1 of formula (II) ##STR23## in which R 1 R 2 N is dimethylamino, pyrrolidino, piperidino or hexamethylenimino, R 3 is methyl and R 7 is amino or R 3 and R 7 together form the group --CH═CH-- 2 or (CH 2 ) 4 .
Claim 6
Dependent Claim 42 words
A pharmaceutical composition for the treatment of conditions mediated through histamine H 2 -receptors which comprises an effective amount to relieve said condition of a compound as claimed in claim 1 together with at least one inert pharmaceutically acceptable carrier or diluent.
Claim 7
Dependent Claim 33 words
A method of treating a condition mediated through histamine H 2 -receptors which comprises administering to a patient an effective amount of a compound as claimed in claim 1 to relieve said condition.

References Cited (Backward Citations)

GB2063253A Cited
GB2075007A Cited
US4450168A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1988-05-20 1988-11-19 1989-05-21 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1992-05-20 1992-11-19 1993-05-21 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1996-05-20 1996-11-19 1997-05-21 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag